Journal of Thrombosis and Haemostasis
Papers 8443
1 page of 845 pages (8,443 results)
A prominent clinical feature of severe Covid-19 infection is respiratory failure associated with pulmonary coagulopathy. Recent reports published in Thrombosis and Haemostasis show that treatment with low-molecular weight heparin (LMWH) decreases mortality in critically ill patients with sepsis-induced hypercoagulation, and thus argue for prophylactic administration of the anticoagulant. In addition, the authors point to non-anticoagulant activities of heparin, in particular anti-inflammatory ef...
#1Arian Arjomandi Rad (Imperial College London)
#2Robert Vardanyan (Imperial College London)
Last. Natalie R Tas ('KCL': King's College London)
view all 3 authors...
Recent and developing literature has begun reporting on the incidence of thromboembolic events associated with COVID-19. Klok et al. analysed 184 SARS-CoV2-positive ICU patients in two Dutch University Hospitals, reporting an incidence of thrombotic complications to be 31%, with Pulmonary Embolism (PE) comprising 81% of these complications. [1] Moreover, Cui et al. reports on a population of 81 ICU patients at the Union Hospital, Wuhan, an incidence of 25% in VTE, also possibly related to worse ...
#1Francisco Sandro Menezes-Rodrigues (UNIFESP: Federal University of São Paulo)H-Index: 4
#2José Gustavo Padrão Tavares (UNIFESP: Federal University of São Paulo)H-Index: 3
Last. Afonso Caricati-Neto (UNIFESP: Federal University of São Paulo)H-Index: 14
view all 8 authors...
Abstract Most severe manifestations of COVID-19 cases, such as multiple organ failure and death, have been linked to coagulation dysfunction markers, such as platelet reduction and increases in prothrombin time, fibrin degradation products and, mainly, D-dimer [1]. A recent paper by Tang et al. [2] in this journal reported that heparin treatment reduced mortality of COVID-19 patients with elevated D-dimer; similar preliminary results have been reported elsewhere [3]. A mounting body of evidence ...
Abstract We appreciate the opportunity to respond to the letter from Dr Gris and colleagues. It is true there were several limitations in our study. However, we still believe that D-dimer level at admission could be an effective and easily available predictor in patients with coronavirus disease 2019 (COVID-19).
#1Pieter M. De Kesel (Ghent University Hospital)
#2Katrien Devreese (UGent: Ghent University)H-Index: 23
#1Nathan T. Connell (Harvard University)H-Index: 4
#2Elisabeth M. Battinelli (Harvard University)H-Index: 16
Last. Jean-Marie Connors (Harvard University)H-Index: 28
view all 3 authors...
Abstract Recently in the Journal of Thrombosis and Haemostasis, Harzallah and colleagues report the results of antiphospholipid antibody testing in a series of 56 patients with confirmed or suspected SARS-CoV-2 infection.[1] Twenty-five patients were found to be positive for lupus anticoagulants, while five patients had either anticardiolipin or anti??2-glycoprotein I antibodies. The isotypes for the anticardiolipin and anti??2-glycoprotein I antibodies were reportedly IgG and IgM, although spec...
#1Ning Tang (HUST: Huazhong University of Science and Technology)H-Index: 1
We appreciate the opportunity to respond to the letter from Dr. Ines Harzallah, et al. Antiphospholipid antibody assays including lupus anticoagulant (LAC), anticardiolipin and anti-beta2-glycoprotein I have also been performed in dozens of our patients, however, very few of them got positive results, we don't think that antiphospholipid antibody exists universally in COVID-19 patients. In addition, two of the three reported cases with antiphospholipid antibodies mentioned in the letter [1] also...
BACKGROUND: Emicizumab is an alternative non-factor approach for treating patients with hemophilia A. However, there is a potential risk of thrombotic events when emicizumab is concomitantly administered with pro-hemostatic therapies. OBJECTIVES: To assess the hemostatic effect in vitro when a plasma-derived factor VIII concentrate containing von Willebrand factor (pdFVIII/VWF) was added to hemophilia A plasma (HAp) in combination with emicizumab. METHODS: HAp and HAp with FVIII inhibitors (HAp-...
#1Xiaobo Yang (HUST: Huazhong University of Science and Technology)H-Index: 1
#2You Shang (HUST: Huazhong University of Science and Technology)H-Index: 20
Dr. Jecko Trachil stressed a possibility of platelet consumption to form pulmonary thrombi in patients with DOVID-19(1) , which coincides with the theory, which we are working on right now, that pulmonary thrombi may be responsible for hypoxemia before typical acute respiratory distress syndrome develops(2) , ie silent hypoxemia called by some experts(3) . As for anti-platelet drugs attenuating thrombi formation, the balance would be too delicate to maintain, because they may block the platelet ...
Top fields of study
Diabetes mellitus